Breaking News on Global Pharmaceutical Technology & Manufacturing

Ingredients: Top Headlines

Onyx contracted for API R&D and manufacturing by UK cancer charity

23-Jul-2014 - Onyx Scientific has been contracted to develop and manufacture APIs for clinical trials by charitable group Cancer Research UK.

Related news

News in brief

ADHD API sales up, specialty opiates down at Johnson Matthey in Q1

23-Jul-2014 - Johnson Matthey’s API business had a mixed fiscal Q1 with gains made in ADHD ingredients and bulk opiates being accompanied by a decline in revenue from specialty opiates.

European Pharmacopoeia plans revisions of elemental impurities guideline

23-Jul-2014 - As the International Conference on Harmonisation (ICH) signs off on a new tripartite guideline related to elemental impurities, the European Pharmacopoeia Commission will revise its texts to ensure consistency. 

New nanotech excipient offers cheaper solubility option say scientists

22-Jul-2014 - Scientists in Sweden have developed a magnesium carbonate-based excipient they claim is a low-cost nanotech alternative to silica for drugmakers struggling to formulate insoluble APIs.

Drug ingredients were key to Ireland's manufacturing growth in 2013 says CSO

21-Jul-2014 - Basic pharmaceuticals including APIs became even more important revenue generators for Ireland in 2013 according to new data released by the Central Statistics Office (CSO).

Janssen's tramadol supply chain ready for DEA's rescheduling deadline

16-Jul-2014 - Janssen Pharmaceuticals is prepared for Tramadol's reclassification by the US Drug Enforcement Administration (DEA) and says the supply of its versions of the opioid analgesic will not be interrupted.

FDA proposed rule could delay import of excipients, PhRMA says

15-Jul-2014 - Although industry group PhRMA has called for the full implementation of a proposed rule that would allow the US FDA to destroy detained drugs deemed to be counterfeit or unapproved, the group also warns that such destruction could lead to manufacturing delays.

Apotex hit with warning letter on troubled API facility in India

09-Jul-2014 - Apotex is getting reprimanded once again for its API facility in Bangalore, India, after the company failed to adequately respond to an FDA Form 483 over data integrity issues, according to an FDA warning letter dated June 16 .

Ingredients: Featured news

Spotlight

Exporters rush to meet Chinese FDA serialisation requirements

Exporters rush to meet Chinese FDA serialisation requirements

Pharmaceutical companies are rushing to respond to shortened deadlines from China’s Food and Drug Administration (CFDA) for...

GSK confident despite endotoxin problems at Canadian vaccine plant

GSK confident despite ongoing endotoxin problems at Canadian flu vaccine plant

GSK is confident it can meet Flulaval production targets ahead of this winter’s flu season despite ongoing...

Marketing agency targets poor interns for GSK paid trials

Marketing agency targets poor interns for GSK paid trials

Representatives for GSK have targeted struggling graduates and unpaid interns as volunteers for clinical trials, saying the...

Roche: ‘If suppliers don’t open up their books, then we are done’

Roche: ‘If suppliers don’t open up their books, then we are done’

Drug raw materials suppliers have not recognised their potential value to biopharmaceutical customers according to Roche which...

Teva's 70+ manufacturing sites could be halved in efficiency drive

Teva's 70+ manufacturing sites could be halved in efficiency drive

Teva could halve its manufacturing network as part of its $2bn-a-year efficiency programme says CFO Eyal Desheh,...

Key Industry Events

 

Access all events listing

Our events, Events from partners...